Functions of epidermal growth factor receptor in cisplatin response of thyroid cells

Biochemical Pharmacology

Volumn 77, Issue 6, 2009, Pages 979-992

  Muscella, Antonella ^a   Urso, Loredana ^a   Calabriso, Nadia ^a   Vetrugno, Carla ^a   Fanizzi, Francesco Paolo ^a   Storelli, Carlo ^a   Marsigliante, Santo ^a  

^a UNIVERSITY OF SALENTO   (Italy)

Author keywords

Cisplatin; EGFR; MMP 2; p38 MAPK; PC Cl3; PKC ; ROS; Thyroid

Indexed keywords

APOCYNIN; CISPLATIN; DIPHENYLIODONIUM SALT; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE A; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE C EPSILON; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SMALL INTERFERING RNA;

ANIMAL CELL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RAT; THYROID CELL;

ANIMALS; APOPTOSIS; CELL LINE; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RATS; REACTIVE OXYGEN SPECIES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; THYROID GLAND; TYRPHOSTINS;

EID: 60649121714     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.12.001     Document Type: Article

References (60)

1. Santini F., Bottici V., Elisei R., Montanelli L., Mazzeo S., Basolo F., et al. Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer. J Clin Endocrinol Metab 87 (2002) 4160-4165
2. Stassi G., Todaro M., Zerilli M., Ricci-Vitiani L., Di Liberto D., Patti M., et al. Thyroid cancer resistance to chemotherapeutic drugs via autocrine production of interleukin-4 and interleukin-10. Cancer Res 63 (2003) 6784-6790
3. Haddad R., Mahadevan A., Posner M.R., and Sullivan C. Long term survival with adjuvant carboplatin, paclitaxel, and radiation therapy in anaplastic thyroid cancer. Am J Clin Oncol 28 (2005) 104-109
4. Istvan A., Megyesi J.K., Kaneto H., Price P.M., and Safirstein R.L. Cisplatin-induced cell death is EGFR/src/ERK signaling dependent in mouse proximal tubule cells. Am J Physiol Renal Physiol 287 (2004) 543-549
5. Prenzel N., Fischer O.M., Streit S., Hart S., and Ullrich A. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 8 (2001) 11-31
6. Murakawa T., Tsuda H., Tanimoto T., Tanabe T., Kitahara S., and Matsubara O. Expression of KIT, EGFR, HER-2 and tyrosine phosphorylation in undifferentiated thyroid carcinoma: implication for a new therapeutic approach. Pathol Int 55 (2005) 757-765
7. Bianco R., Gelardi T., Damiano V., Ciardiello F., and Tortora G. Rational bases for the development of EGFR inhibitors for cancer treatment. Int J Biochem Cell Biol 34 (2007) 1416-1431
8. Winograd-Katz S.E., and Levitzki A. Cisplatin induces PKB/Akt activation and p38/MAPK (MAPK) phosphorylation of the EGF receptor. Oncogene 25 (2006) 7381-7390
9. Xia Z., Dickens M., Raingeaud J., Davis R.J., and Greenberg M.E. Opposing effects of ERK and JNK-p38/MAPK MAP kinases on apoptosis. Science 270 (1995) 1326-1331
10. Mendes O., Kim H.T., Lungu G., and Stoica G. MMP-2 role in breast cancer brain metastasis development and its regulation by TIMP 2 and ERK 1/2. Clin Exp Metastasis 24 (2007) 341-351
11. Ramer R., Eichele K., and Hinz B. Upregulation of tissue inhibitor of matrix metalloproteinase-1 confers the anti-invasive action of cisplatin on human cancer cells. Oncogene 26 (2007) 5822-5827
12. Cowden Dahl K.D., Symowicz J., Ning Y., Gutierrez E., Fishman D.A., Adley B.P., et al. Matrix metalloproteinase 9 is a mediator of epidermal growth factor-dependent E-cadherin loss in ovarian carcinoma cells. Cancer Res 68 12 (2008) 4606-4613
13. Hao L., Du M., Lopez-Campistrous A., and Fernandez-Patron C. Agonist-induced activation of matrix metalloproteinase-7 promotes vasoconstriction through the epidermal growth factor-receptor pathway. Circ Res 94 (2004) 68-76
14. Lucchesi P.A., Sabri A., Belmadani S., and Matrougui K. Involvement of metalloproteinases 2/9 in epidermal growth factor receptor transactivation in pressure-induced myogenic tone in mouse mesenteric resistance arteries. Circulation 110 (2004) 3587-3593
15. Masuda H., Tanaka T., and Takahama U. Cisplatin generates superoxide anion by interaction with DNA in a cell-free system. Biochem Biophys Res Commun 203 (1994) 1175-1180
16. Bragado P., Armesilla A., Silva A., and Porras A. Apoptosis by cisplatin requires p53 mediated p38/MAPKalpha MAPK activation through ROS generation. Apoptosis 12 (2007) 1733-1742
17. Muscella A., Urso L., Calabriso N., Ciccarese A., Migoni D., Fanizzi F.P., et al. Differential response of normal, dedifferentiated and transformed thyroid cell lines to cisplatin treatment. Biochem Pharmacol 71 (2005) 50-60
18. Urso L., Muscella A., Calabriso N., Ciccarese A., Fanizzi F.P., Migoni D., et al. Differential functions of PKC-delta and PKC-zeta in cisplatin response of normal and transformed thyroid cells. Biochem Biophys Res Commun 337 (2005) 297-305
19. Fusco A., Berlingieri M.T., Di Fiore P.P., Portella G., Grieco M., and Vecchio G. One- and two-step transformations of rat thyroid epithelial cells by retroviral oncogenes. Mol Cell Biol 7 (1987) 3365-3370
20. Berlingieri M.T., Santoro M., Battaglia C., Grieco M., and Fusco A. The adenovirus E1A gene blocks the differentiation of a thyroid epithelial cell line, however the neoplastic phenotype is achieved only after cooperation with other oncogenes. Oncogene 8 (1993) 249-255
21. Nørby J.G. Coupled assay of Na+/K + ATPase activity. In: Colowick S.P., and Kaplan N.O. (Eds). Methods in enzymology vol. 156 (1988), Academic Press, New York 116-119 [part P]
22. Kochhar S., Chuard N., and Hottinger H. Glutamate 264 modulates the pH dependence of the NAD (+)-dependent d-lactate dehydrogenase. J Biol Chem 267 (1992) 20298-20301
23. Skehan P., Storeng R., Scudiero D., Monks A., McMahon J., Vistica D., et al. New colorimetric cytotoxicity assay for anticancerdrug screening. J Natl Cancer Inst 82 (1990) 1107-1112
24. Oliveira H.R., Verlengia R., Carvalho C.R., Britto L.R., Curi R., and Carpinelli A.R. Pancreatic beta-cells express phagocyte-like NAD(P)H oxidase. Diabetes 52 (2003) 1457-1563
25. Partik G., Hochegger K., Schorkhuber M., and Marian B. Inhibition of epidermal-growth-factor-receptor-dependent signalling by tyrphostins A25 and AG1478 blocks growth and induces apoptosis in colorectal tumor cells in vitro. J Cancer Res Clin Oncol 125 (1999) 379-388
26. Kanda Y., Mizuno K., Kuroki Y., and Watanabe Y. Thrombin-induced p38 mitogen-activated protein kinase activation is mediated by epidermal growth factor receptor transactivation pathway. Br J Pharmacol 132 (2001) 1657-1664
27. Bain J., Plater L., Elliott M., Shpiro N., Hastie C.J., McLauchlan H., et al. The selectivity of protein kinase inhibitors: a further update. Biochem J 408 (2007) 297-315
28. Marsigliante S., Mascella A., Elia M.G., Greco S., and Storelli C. Angiotensin II AT1 receptor stimulates Na + -K + ATPase activity through a pathway involving PKC-z in rat thyroid cells. J Physiol 546 (2003) 461-470
29. Martiny-Baron G., Kazanietz M.G., Mischak H., Blumberg P.M., Kochs G., Hug H., et al. Selective inhibition of protein kinase C isozymes by the indolcarbazole Go6976. J Biol Chem 268 (1993) 9194-9197
30. Yedovitzky M., Mochly-Rosen D., Johnson J.A., Gray M.O., Ron D., Abramovitch E., et al. Translocation inhibitors define specificity of protein kinase C isoenzymes in pancreatic beta-cells. J Biol Chem 272 January (3) (1997) 1417-1420
31. Yeung S.C., Chiu A.C., Vassilopoulou-Sellin R., and Gagel R.F. The endocrine effects of nonhormonal antineoplastic therapy. Endocr Rev 19 (1998) 144-172
32. Stuart N.S., Woodroffe C.M., Grundy R., and Cullen M.H. Long-term toxicity of chemotherapy for testicular cancer-the cost of cure. Br J Cancer 61 (1990) 479-484
33. Kanamori A., Abe Y., Yajima Y., Manabe Y., and Ito K. Epidermal growth factor receptors in plasma membranes of normal and diseased human thyroid glands. J Clin Endocrinol Metab 68 (1989) 899-903
34. Gabler B., Aicher T., Heiss P., and Senekowitsch-Schmidtke R. Growth inhibition of human papillary thyroid carcinoma cells and multicellular spheroids by anti-EGF-receptor antibody. Anticancer Res 17 (1997) 3157-3159
35. Bergstrom J.D., Westermark B., and Heldin N.E. Epidermal growth factor receptor signalling activates met in human anaplastic thyroid carcinoma cells. Exp Cell Res 259 (2000) 293-299
36. Yin F., Giuliano A.E., and Van Herle A.J. Signal pathways involved in apigenin inhibition of growth and induction of apoptosis of human anaplastic thyroid cancer cells (ARO). Anticancer Res 19 (1999) 4297-4303
37. Zwang Y., and Yarden Y. p38/MAPK MAP kinase mediates stress-induced internalization of EGFR: implications for cancer chemotherapy. EMBO J 25 (2006) 4195-4206
38. Forsyth C.B., Banan A., Farhadi A., Fields J.Z., Tang Y., Shaikh M., et al. Regulation of oxidant-induced intestinal permeability by metalloprotease-dependent epidermal growth factor receptor signaling. J Pharmacol Exp Ther 321 (2007) 84-97
39. Garcia R., Franklin R.A., and McCubrey J.A. Cell death of MCF-7 human breast cancer cells induced by EGFR activation in the absence of other growth factors. Cell Cycle 5 (2006) 1840-1846
40. Le X.F., Marcelli M., McWatters A., Nan B., Mills G.B., O'Brian C.A., et al. Heregulin-induced apoptosis is mediated by down-regulation of Bcl-2 and activation of caspase-7 and is potentiated by impairment of protein kinase C alpha activity. Oncogene 20 (2001) 8258-8269
41. Brozovic A., and Osmak M. Activation of mitogen-activated protein kinases by cisplatin and their role in cisplatin-resistance. Cancer Lett 251 (2007) 1-16
42. Zechner D., Craig R., Hanford D.S., McDonough P.M., Sabbadini R.A., and Glembotski C.C. MKK6 activates myocardial cell NF-kappaB and inhibits apoptosis in a p38/MAPK mitogen-activated protein kinase-dependent manner. J Biol Chem 273 (1998) 8232-8239
43. Roulston A., Reinhard C., Amiri P., and Williams L.T. Early activation of c-Jun N-terminal kinase and p38/MAPK kinase regulate cell survival in response to tumor necrosis factor alpha. J Biol Chem 273 (1998) 10232-10239
44. Ivanov V.N., and Ronai Z. p38/MAPK protects human melanoma cells from UV-induced apoptosis through down-regulation of NF-kappaB activity and Fas expression. Oncogene 19 (2000) 3003-3012
45. Kummer J.L., Rao P.K., and Heidenreich K.A. Apoptosis induced by withdrawal of trophic factors is mediated by p38/MAPK mitogen-activated protein kinase. J Biol Chem 272 (1997) 20490-20494
46. Kawasaki H., Morooka T., Shimohama S., Kimura J., Hirano T., Gotoh Y., et al. Activation and involvement of p38/MAPK mitogen-activated protein kinase in glutamate-induced apoptosis in rat cerebellar granule cells. J Biol Chem 272 (1997) 18518-18521
47. Schwenger P., Bellosta P., Vietor I., Basilico C., Skolnik E.Y., and Vilcek J. Sodium salicylate induces apoptosis via p38/MAPK mitogen-activated protein kinase but inhibits tumor necrosis factor-induced c-Jun N-terminal kinase/stress-activated protein kinase activation. Proc Natl Acad Sci USA 94 (1997) 2869-2873
48. Joneson T., and Bar-Sagi D. Suppression of Ras-induced apoptosis by the Rac GTPase. Mol Cell Biol 19 September (9) (1999) 5892-5901
49. Di-Capua N., Sperling O., and Zoref-Shani E. Protein kinase C-epsilon is involved in the adenosine-activated signal transduction pathway conferring protection against ischemia-reperfusion injury in primary rat neuronal cultures. J Neurochem 84 (2003) 409-412
50. Baines C.P., Song C.X., Zheng Y.T., Wang G.W., Zhang J., Wang O.L., et al. Protein kinase Cepsilon interacts with and inhibits the permeability transition pore in cardiac mitochondria. Circ Res 92 (2003) 873-880
51. Basu A., Lu D., Sun B., Moor A.N., Akkaraju G.R., and Huang J. Proteolytic activation of protein kinase C-epsilon by caspase-mediated processing and transduction of antiapoptotic signals. J Biol Chem 277 (2002) 41850-41856
52. Gonzalez-Guerrico A.M., and Kazanietz M.G. Phorbol ester-induced apoptosis in prostate cancer cells via autocrine activation of the extrinsic apoptotic cascade: a key role for protein kinase C delta. J Biol Chem 280 (2005) 38982-38991
53. Ohmori T., and Arteaga C.L. Protein kinase C epsilon translocation and phosphorylation by cis-diamminedichloroplatinum(II) (CDDP): potential role in CDDP-mediated cytotoxicity. Cell Growth Differ 9 (1998) 345-353
54. Lee Y.J., Soh J.W., Jeoung D.I., Cho C.K., Jhon G.J., Lee S.J., et al. PKC epsilon -mediated ERK1/2 activation involved in radiation-induced cell death in NIH3T3 cells. Biochim Biophys Acta 1593 2/3 (2003) 219-229
55. Knauf J.A., Elisei R., Mochly-Rosen D., Liron T., Chen X.N., Gonsky R., et al. Involvement of protein kinase Cepsilon (PKC epsilon) in thyroid cell death. A truncated chimeric PKC epsilon cloned from a thyroid cancer cell line protects thyroid cells from apoptosis. J Biol Chem 274 (1999) 23414-23425
56. Carpenter G. Receptors for epidermal growth factor and other polypeptide mitogens. Annu Rev Biochem 56 (1987) 881-914
57. Rajagopalan S., Meng X.P., Ramasamy S., Harrison D.G., and Galis Z.S. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J Clin Invest 98 (1996) 2572-2579
58. Siwik D.A., Pagano P.J., and Colucci W.S. Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am J Physiol Cell Physiol 280 (2001) 53-59
59. Grote K., Flach I., Luchtefeld M., Akin E., Holland S.M., Drexler H., et al. Mechanical stretch enhances mRNA expression and proenzyme release of matrix metalloproteinase-2 (MMP-2) via NAD (P)H oxidase derived reactive oxygen species. Circ Res 92 (2003) 80-86
60. Thomas S.M., and Grandis J.R. Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treat Rev 30 (2004) 255-268